385
Participants
Start Date
September 27, 2018
Primary Completion Date
April 1, 2021
Study Completion Date
November 2, 2021
Peficitinib
Oral
Plaebo
Oral
Disease-modifying antirheumatic drugs (DMARDs)
"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
Site CN00048, Anhui
Site CN00045, Beijing
Site CN00054, Beijing
Site CN00050, Bengbu
Site CN00061, Changchun
Site CN00032, Changsha
Site CN00076, Chenzhou
Site CN00071, Guangdong
Site CN00016, Guangzhou
Site CN00052, Guangzhou
Site CN00063, Guangzhou
Site CN00072, Guangzhou
Site CN00058, Inner Mongolia
Site CN00074, Jieyang
Site CN00028, Jilin
Site CN00069, Jining
Site CN00064, Jiujiang
Site CN00046, Kunming
Site CN00060, Nanjing
Site CN00070, Nanjing
Site CN00068, Ningbo
Site CN00075, Pingxiang
Site CN00066, Qingdao
Site CN00056, Shanghai
Site CN00047, Shantou
Site CN00053, Sichuan
Site CN00057, Tianjin
Site CN00062, Tianjin
Site CN00059, Wuhan
Site CN00067, Xining
Site CN00065, Xuzhou
Site CN00073, Zhengzhou
Site CN00049, Zhuzhou
Site KR00037, Gwangju
Site KR00036, Incheon
Site KR00033, Seoul
Site KR00034, Seoul
Site KR00035, Seoul
Site TW00022, Taichung
Site TW00023, Taichung
Site TW00024, Taichung
Site TW00025, Taipei
Site TW00026, Taipei
Astellas Pharma China, Inc.
INDUSTRY